| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director, 10% Owner
1 company
Katz Ilan serves as a Director, 10% Owner at SABS. Across recent SEC filings that breaks down to 3 buys and 0 sells. Those positions are worth an estimated $15K at current prices.
The biggest single holding is SABS (~$15K). Net of sales, the recent Form 4 record there shows accumulation of 418,700 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 13, 2021 | SABS Sab Biotherapeutics, Inc. | - | Buy | 500 | $10.11 | $5,052.50 | +50.0% | -24.1% | -92.4% | |
| Oct 1, 2021 | SABS Sab Biotherapeutics, Inc. | Director, 10% Owner | Buy | 1,000 | $10.09 | $10,090.00 | New | -21.0% | -93.0% | |
| Jan 14, 2021 | SABS Sab Biotherapeutics, Inc. | Director, 10% Owner | Buy | 417,200 | $10.00 | $4,172,000.00 | +15.9% | - | - |